Today: 19 May 2026
Browse Category

Biotechnology 3 November 2025 - 13 November 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine shares surged Thursday after the company received final approval to expand its FDA-regulated Phase 1/2a trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. The firm also filed for a registered direct offering of shares and pre-funded warrants, raising new capital but prompting dilution concerns among investors. The trial now includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah.
13 November 2025
··
Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte reported Q3 revenue of $753,000, with $703,000 from Symvess sales, and a net loss of $17.5 million (GAAP EPS −$0.11). The company said 25 Value Analysis Committee approvals now cover 92 U.S. hospitals, with 16 hospitals ordering Symvess. Positive two-year Phase 3 dialysis trial results were presented, and an IND was submitted for a coronary bypass graft study in 2026.
12 November 2025
··
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings reported a 62% complete response rate at 6 months in its pivotal Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk, BCG-unresponsive NMIBC with CIS. The company enrolled 125 patients, above target. Shares surged as much as 62% pre-market after the update. Safety data showed 42% of patients had treatment-related adverse events, mostly mild.
11 November 2025
···
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Ethos Financial Group disclosed a new stake in Viking Therapeutics, acquiring 10,548 VKTX shares valued at about $280,000. VKTX closed Friday at $36.77 on volume of 4.65 million. Recent insider sales totaled 111,359 shares, while institutional ownership stands near 76%. Clinical updates include positive VK2735 obesity data and ongoing Phase 3 enrollment.
9 November 2025
·
Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

The FDA placed a clinical hold on Tenaya’s MyPEAK-1 trial for TN-201, requiring protocol changes for patient monitoring and immunosuppression. Tenaya reported new interim data showing six treated patients had increased MyBP-C protein and improved cardiac biomarkers, with all six no longer symptomatic. Shares dropped over 20% after the hold was announced. The company does not expect data timelines to change.
8 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia said a patient in its Phase 3 MAGNITUDE trial died after severe liver toxicity; FDA clinical holds on MAGNITUDE and MAGNITUDE-2 remain. NTLA shares fell as RBC cut its price target to $9, citing increased risk. The company reported $669.9 million in cash and securities, expecting its runway to last into mid-2027. Work continues on its hereditary angioedema program.
7 November 2025
···
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics reported Q3 2025 revenue of $67.5 million, up 13% sequentially but below analyst expectations, and a net loss of $91.3 million, or $0.25 per share. Gross margin rose to 43%. Management reaffirmed full-year revenue guidance of $250–$300 million. Over 80 U.S. treatment centers are now active, and cash reserves totaled $307 million at quarter’s end.
6 November 2025
···
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Lunai Bioworks (NASDAQ: LNAI) shares surged over 15% to around $1 after announcing preclinical success in pancreatic cancer immunotherapy on Nov. 5, 2025. The stock remains down more than 85% year-over-year and trades near all-time lows after a 10:1 reverse split in September. Lunai is pre-revenue, posted a $178 million net loss over the past year, and faces severe liquidity issues.
5 November 2025
···
Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals shares fell 15% in the past week to around $5, down 55% from their 52-week high. Q3 2025 revenue missed estimates at $5 million, with net loss widening to $162.3 million. The company announced a $30 million milestone payment from Roche/Genentech and a CEO transition, with Najat Khan set to take over in January. Recursion holds about $785 million in cash, enough to fund operations through 2027.
5 November 2025
··
‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

ESA has launched the HOBI‑WAN pilot to test microbial protein production from hydrogen, oxygen, and CO₂ in microgravity, with OHB System AG and Solar Foods as partners. An eight-month ground phase begins now, ahead of an ISS flight model. Indian researchers report yeast surviving Mars-like shock waves and toxic salts. Solar Foods shares traded near €5.5 in Helsinki, OHB SE closed at €106 in Frankfurt.
5 November 2025
····
COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways’ stock traded near $6 on Nov. 4, 2025, flat after a recent pullback and well above mid-year lows. The company reported a net loss of $137.7 million in Q3, with $185.9 million in cash on hand. Its lead psilocybin therapy met the primary endpoint in a Phase 3 trial for treatment-resistant depression in June. COMPASS is accelerating commercial plans and expects key data readouts in 2026.
4 November 2025
·
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis reported 2024 revenue of $9.3 billion, up 9% from 2023, with gross margins near 72% and net profit margin around 29%. Shares traded at $130–$135 in November 2025, down from a 52-week high of $180. The company raised its dividend by 15% to $2.00 per share. Analysts’ average 12-month target is $188, though some issued downgrades in late 2025 amid slowing growth.
4 November 2025
··
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

Sarepta Therapeutics shares plunged nearly 80% in 2025, falling from a high of $138.81 to around $15 after its Phase 3 ESSENCE trial failed and the FDA halted gene therapy trials following patient deaths. Q3 revenue beat estimates at $399.4 million, but the company posted a $179.9 million net loss. Sarepta restricted Elevidys sales to ambulatory patients after the FDA intervention. Analyst consensus is Hold, with a $34.50 average price target.
4 November 2025
··
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 November 2025
··
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou Biosciences reported its off-the-shelf CAR-T therapy vispa-cel achieved a 64% complete remission rate in lymphoma, with 51% of patients cancer-free after one year. In multiple myeloma, CB-011 showed a 92% overall response rate. Shares of Caribou more than doubled after the Nov. 3 announcement. No graft-vs-host disease was observed, though one fatal toxicity occurred.
3 November 2025
··
1 … 11 12 13 14 15 … 17

Stock Market Today

  • Nifty 50 Index Faces Pressure Amid Rising Indian Bond Yields and Rupee Decline
    May 19, 2026, 12:21 AM EDT. The Nifty 50 Index fell to ₹23,650, down 10% from this year's peak, amid economic concerns stemming from the US-Iran war and India's reliance on Gulf oil. Inflation rose to 3.48% in April, the fastest in over a year, raising expectations of Reserve Bank of India (RBI) interest rate hikes. Indian bond yields surged, with 10-year yields climbing to 7.13%, the highest since May 2024, raising borrowing costs for companies. Concurrently, the Indian rupee weakened significantly, with USD/INR reaching a record 96.35, reducing foreign investor attractiveness. Technical analysis shows a bearish double-top pattern on the Nifty 50, suggesting potential further declines toward ₹23,000 support.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Bitmine Shares Fall as Lee Raises Ethereum Exposure

Bitmine Shares Fall as Lee Raises Ethereum Exposure

18 May 2026
Bitmine shares fell 7.5% to $18.37 Monday after the company reported its ETH holdings rose to 5.28 million tokens, or 4.37% of supply. Total crypto, cash, and “moonshot” holdings dropped to $12.6 billion from $13.4 billion a week earlier as Ether slid 4.1% to $2,098. Chairman Tom Lee said Bitmine bought 71,672 ETH last week. About 89% of Bitmine’s ETH is staked, generating $289 million in annualized revenue.
Go toTop